Clinical outcomes and quality of life associated with eculizumab in patients with late-onset myasthenia gravis
IntroductionLate-onset myasthenia gravis (LOMG) features prominent immunosenescence, high myasthenic crisis risk, and refractoriness due to comorbidities limiting conventional immunosuppressants, leading to poor prognosis. Eculizumab, which blocks comp…